Alzheimer's Disease Clinical Trial
— PMPBB3/AV45Official title:
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
Dementia is a common neurodegenerative syndrome in aged population. Alzheimer's disease (AD)
is the most common disease. The main pathological findings in AD include senile plaques (SP)
and neurofibrillary tangles (NFT). The b-amyloid is the main peptide in SP and tau protein is
the main finding in NFT. In addition, b-amyloid is considered as a disease biomarker, but the
severity of AD is related with the tau protein.
Recently a new tracer 18F-PM-PBB3 has been introduced in tau PET images. In a prelimary study
with the 18F-PM-PBB3, the tau PET scan provide a good tool to evaluate tau deposition pattern
among healthy volunteers, and patients with mild and moderate dementia due to AD. In this
study we will enroll 20 healthy controls, 20 amnestic mild cognitive impairment patients
(aMCI), 20 mild-moderate dementia due to AD patients and 10 other dementia such as
frontotemporal dementia patients. All of the subjects will receive 18F-PM-PBB3 tau PET scan,
and 18F-flobetapir (AV-45) amyloid PET scan, brain magnetic resonance images and clinical
evaluation. We will follow up the clinical features for 2 years to understand the disease
progression, disease conversion from aMCI to AD.
The study aims to investigate the deposition patterns of tau protein with 18F-PM-PBB3 and
amyloid protein with 18F-flobetapir in patients with amnestic mild cognitive impairment due
to AD, mild to moderate degree of dementia due to AD and healthy controls. The study will
provide the information of these two proteins in different stages of dementia patients. The
results may help the strategy in selection of anti-dementia drugs in the pharmaceutical
company and industry and reduce the economic burden for the society. The study also can
improve the understanding of Alzheimer's disease in academic research.
Status | Recruiting |
Enrollment | 70 |
Est. completion date | January 23, 2021 |
Est. primary completion date | January 23, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 45 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Patient with probable AD (Appendix I) Inclusion criteria 1. Age ranges from 45~90 years 2. Patients fulfill the criteria of probable AD (DSM IV and NINCDS-ADRDA) 3. Mild cognitive impairment to moderate dementia (CDR: 0.5 to 2.0 or MMSE: 10-25) 4. Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study Patient with amnestic MCI due to AD criteria (Appendix II: criteria proposed by world ADNI) Inclusion criteria 1. Age ranges from 45~90 years 2. Patients fulfill the criteria of aMCI (The early aMCI and late aMCI were proposed by world ADNI) 3. Amnestic mild cognitive impairment (CDR: 0.5 or MMSE: 26-30, with logical memory >=7) 4. Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study Patients with probable FTD (Appendix III) 1, 2, 3 Inclusion criteria 1. Age ranges from 45~90 years 2. Patients fulfill the criteria of probable FTD 3. Mild cognitive impairment to moderate dementia (CDR: 0.5 to 2.0 or MMSE: 10-25) 4. Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study Healthy control Inclusion criteria 1. Age ranges from 45~90 years 2. Normal cognitive function (CDR: 0 or MMSE: 26-30) 3. Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study Exclusion Criteria: - 1) Implantation of metal devices including cardiac pacemaker, intravascular metal devices. 2) Major systemic diseases including coronary arterial disease, heart failure, uremia, hepatic failure, prominent strokes, acute myocardial infarction, poorly controlled diabetes, previous head injury, intracranial operation, hypoxia, sepsis or severe infectious diseases 3) Major psychiatric disorders, drug or alcohol abuse and major depression 4) Pregnant women or breast- feeding women 5) Subjects in whom MRI was contraindicated 6) History of severe allergic or anaphylactic reactions particularly to the tested drugs 7) History of positive test for human immunodeficiency virus (HIV) 8) Indication of impaired liver function as shown by an abnormal liver function profile at screening (eg. repeated values of aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ? 3X the upper limit of normal values) |
Country | Name | City | State |
---|---|---|---|
Taiwan | Chang Gung Memorial Hospital,Linkou | Taoyuan | Guishan Dist, |
Lead Sponsor | Collaborator |
---|---|
Chang Gung Memorial Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tau Distribution | Tau Distribution Among healthy controls, amnestic mild cognitive impairment patients (aMCI), mild-moderate dementia due to AD and other dementia such as frontotemporal dementia. Subjects Measured by Standardized Uptake Value Ratio (SUVR) as Assessed by 18F-PM-PBB3 tau PET Scan and AV45 amyloid pet scan. | 1 YEAR |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02089555 -
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
|
N/A |